Identification of Therapeutic Targets in Metastatic Gastric Cancer

Last updated: April 22, 2026
Sponsor: Chinese University of Hong Kong
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neoplasm Metastasis

Digestive System Neoplasms

Stomach Cancer

Treatment

N/A

Clinical Study ID

NCT07551440
2023.117
  • Ages 18-80
  • All Genders

Study Summary

This is a pilot study aiming at identifying novel therapeutic molecular targets in patients with gastric cancer with lymph nodes or distant metastasis. All patients who are diagnosed with gastric cancer with metastases in the Prince of Wales Hospital will be screened for eligibility.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patients age >= 18, <= 80 years old

  2. Performance status (WHO) <=2

  3. Gastric adenocarcinoma with lymph node metastasis or distant metastasis such asliver metastases, lung metastases, bone metastases, peritoneum metastases

  4. Patients with isolated ovarian metastasis could be included

  5. Patients who will be undergoing neoadjuvant chemotherapy/ target therapy/immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy

  6. Ability to give written consent before the commencement of treatment

Exclusion

Exclusion Criteria:

  1. Patient who will not be undergoing neoadjuvant chemotherapy/ target therapy/immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy

  2. Pregnancy or breastfeeding

  3. Patients with irreversible coagulation disorders

Study Design

Total Participants: 100
Study Start date:
October 15, 2023
Estimated Completion Date:
October 31, 2033

Connect with a study center

  • The Chinese University of Hong Kong

    Hong Kong, 0000
    Hong Kong

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.